G1 Therapeutics Inc (GTHX) Short Interest Update

G1 Therapeutics Inc (NASDAQ:GTHX) saw a large growth in short interest in the month of December. As of December 29th, there was short interest totalling 697,343 shares, a growth of 29.0% from the December 15th total of 540,660 shares. Approximately 4.3% of the shares of the stock are sold short. Based on an average daily volume of 124,734 shares, the days-to-cover ratio is presently 5.6 days.

G1 Therapeutics (NASDAQ:GTHX) opened at $23.04 on Friday. G1 Therapeutics has a fifty-two week low of $12.04 and a fifty-two week high of $28.67. The company has a market capitalization of $653.08 and a P/E ratio of -10.72.

In related news, insider Mark A. Velleca sold 7,500 shares of the company’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $20.01, for a total value of $150,075.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the company’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $20.01, for a total value of $4,002,000.00. The disclosure for this sale can be found here. Insiders sold a total of 542,156 shares of company stock valued at $10,761,689 in the last ninety days.

Institutional investors have recently made changes to their positions in the business. RA Capital Management LLC purchased a new stake in shares of G1 Therapeutics in the second quarter valued at approximately $46,813,000. FMR LLC purchased a new stake in shares of G1 Therapeutics in the second quarter valued at approximately $34,093,000. Franklin Resources Inc. purchased a new stake in shares of G1 Therapeutics in the second quarter valued at approximately $10,651,000. Hillhouse Capital Management Ltd. purchased a new stake in shares of G1 Therapeutics in the second quarter valued at approximately $7,848,000. Finally, Laurion Capital Management LP purchased a new stake in shares of G1 Therapeutics in the second quarter valued at approximately $3,488,000. 43.25% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have commented on the company. Zacks Investment Research cut G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Cowen reissued a “buy” rating on shares of G1 Therapeutics in a report on Wednesday, November 8th. BidaskClub raised G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 3rd. Finally, BTIG Research assumed coverage on G1 Therapeutics in a report on Tuesday, December 19th. They set a “buy” rating and a $38.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $31.40.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/01/14/g1-therapeutics-inc-gthx-short-interest-update.html.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply